Advisers to the U.S. Food and Drug Administration (FDA) voiced support on May 18 for Pfizer’s maternal RSV vaccine even after several expressed concerns over premature births.

The vaccine was 81.8 percent efficacious through 90 days after birth against severe lower respiratory tract illness due to RSV. The efficacy dropped to 69.4 percent after another 90 days.

But multiple experts expressed concerns about the risk of the vaccine causing premature births, a risk found in a similar product made by GlaxoSmithKline that prompted the company to halt testing in 2022. In Pfizer’s trial, there were more premature deliveries in the vaccinated arm than the placebo arm—5.7 percent in the former versus 4.7 percent in the latter.

https://www.zerohedge.com/medical/fda-advisers-back-maternal-rsv-vaccine-pfizer-says-safety-concerns-can-be-studied-post